Seeking Alpha

Oncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung...

Oncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung cancer drug Stimuvax. He asserts the drug is poorly designed, fails to improve lung cancer survival and is not likely to pass its phase III testing trials. 
Comments (5)
  • redplate
    , contributor
    Comments (59) | Send Message
     
    Still another false and misleading 'opinion piece' written by a short hack. There are few verifiable facts, and a majority of the comments/opinions are proven to be false.
    25 Jul 2011, 12:36 PM Reply Like
  • Sedric
    , contributor
    Comments (600) | Send Message
     
    This site is an enabler of illegal stock manipulatr IMO.
    25 Jul 2011, 07:24 PM Reply Like
  • dabills
    , contributor
    Comments (3) | Send Message
     
    I'm glad I bought some ONCY calls last Friday, after reading Redplate's comments and reviewing the following link -- sites.google.com/site/...
    31 Jul 2011, 04:07 PM Reply Like
  • redplate
    , contributor
    Comments (59) | Send Message
     
    if you bought ONCY it was the wrong stock dude. At least get the trade symbol right.
    red
    1 Aug 2011, 09:57 AM Reply Like
  • dabills
    , contributor
    Comments (3) | Send Message
     
    It was indeed ONTY. I should have re-read before hitting send. My bad.
    2 Aug 2011, 08:55 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|